Loading comparison data...
Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Compare FINGOLIMOD (Fingolimod) and PONESIMOD (PONVORY) — clinical data, side effects, and patient experiences.
Fingolimod, Gilenya · Other
How it works
12.1 Mechanism of Action Fingolimod is metabolized by sphingosine kinase to the active metabolite, fingolimod-phosphate. Fingolimod-phosphate is a sphingosine 1-phosphate receptor ...
Approved for
PONVORY, Ponvory · S1P Receptor Modulator
How it works
12.1 Mechanism of Action Ponesimod is a S1P receptor 1 modulator that binds with high affinity to S1P receptor 1. Ponesimod blocks the capacity of lymphocytes to egress from lymph ...
Approved for
Estimated frequency (%) based on clinical trial data
No head-to-head clinical studies found for FINGOLIMOD vs PONESIMOD.
FINGOLIMOD is a Other, while PONESIMOD belongs to the S1P Receptor Modulator class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles.
Both medications are approved for to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, to include clinically isolated syndrome. When two drugs treat the same condition, the choice between them often depends on the patient's medical history, other medications, tolerability, and prescriber preference.
FINGOLIMOD carries 4 FDA warnings. PONESIMOD carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..
This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.